Top Markets
Coin of the day
Boston Scientific Corporation Boston Scientific Corporation

Boston Scientific Corporation

BSX
Classement en actions #340
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Prix de l'action
$48.86
Capitalisation boursière
$72.62B
Changement (1 jour)
1.69%
Changement (1 an)
-54.20%
Pays
US
Échange Boston Scientific Corporation (BSX)

Catégorie

Bénéfices pour Boston Scientific Corporation (BSX)
Bénéfices en Jun 2026 TTM : $3.86B
Selon les derniers rapports financiers de Boston Scientific Corporation, les bénéfices actuels de l'entreprise sont de $3.86B. En 2024, l'entreprise a réalisé un bénéfice de $2.28B, une augmentation par rapport à celui de 2023 qui était de $1.99B. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Boston Scientific Corporation de 2000 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $3.86B 14.06%
2025 $3.39B 48.33%
2024 $2.28B 14.96%
2023 $1.99B 73.97%
2022 $1.14B 6.04%
2021 $1.08B -1,462.03%
2020 $-79.00M -111.50%
2019 $687.00M -51.69%
2018 $1.42B 52.41%
2017 $933.00M 427.12%
2016 $177.00M -127.23%
2015 $-650.00M 27.70%
2014 $-509.00M 128.25%
2013 $-223.00M -94.57%
2012 $-4.11B -739.72%
2011 $642.00M -160.40%
2010 $-1.06B -18.73%
2009 $-1.31B -35.60%
2008 $-2.03B 256.94%
2007 $-569.00M -83.90%
2006 $-3.54B -496.75%
2005 $891.00M -40.36%
2004 $1.49B 132.35%
2003 $643.00M 17.12%
2002 $549.00M 1,147.73%
2001 $44.00M -91.65%
2000 $527.00M 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
$7.51B 94.54%
US
$5.15B 33.33%
US
$5.56B 44.08%
IE
$1.42B -63.28%
US
- -
DE